iCo Therapeutics Inc.'s Profile

iCo Therapeutics Inc. is a Vancouver-based reprofiling company focused on redosing or reformulating drugs with clinical history for new or expanded indications. iCo has exclusive worldwide rights to three products: iCo-007, in Phase 2 for the treatment of Diabetic Macular Edema (DME), iCo-008 (Bertilimumab), a product with Phase 2 clinical history to be developed for sight-threatening diseases; and an oral Amphotericin B delivery system for life-threatening infectious diseases. Immune Pharmaceuticals licensed systemic rights to iCo-008 in June 2011.

Primary date from Phase 2 are expected in March/April of 2014 and End Point Data is set for August/September of 2014.

iCo Therapeutics trades on the TSX-Venture exchange under the symbol "ICO" and trades on the US QX Exchange under the symbol "ICOTF"